Considering c-Myc protein is un-druggable and lack obvious pockets where small molecules or drugs can bind40, interruption of c-Myc regulatory units like ACSL4 might be a promising alternative to indirectly target c-Myc protein in HCC. Here, ACSL4 is linked to hepatocellular carcinoma.